Physician profile
Deborah Ding
NPI 1689805129
$5,482.27
in general payments reported to CMS, 2019-2025
56 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $1,216 · 2023: $1,311 · 2024: $1,146 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,609 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.96 |
| Education | $297.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $463.82 | 2022-2025 | Lynparza, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $442.28 | 2023-2025 | |
| Seagen INC. | $388.94 | 2021-2025 | Tukysa, Padcev, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $278.09 | 2022-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $273.39 | 2022-2025 | Darzalex, Tecvayli, Erleada |
| Lilly USA, LLC | $269.35 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $216.84 | 2021-2023 | Epkinly, Imbruvica |
| Pfizer INC. | $208.80 | 2023-2025 | |
| Genzyme Corporation | $198.31 | 2021-2025 | |
| Beigene USA, INC. | $186.14 | 2022-2025 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $157.18 | 2021-2024 | Onivyde, Somatuline Depot |
| Daiichi Sankyo INC. | $148.27 | 2021-2025 | Enhertu |
| Celgene Corporation | $146.64 | 2023-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $137.85 | 2022-2025 | Keytruda |
| Genentech USA, INC. | $135.45 | 2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.